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Severe Chronic Venous Insufficiency:
Magnitude of the Problem and Consequences
Susan Tsai, MD, Anna Dubovoy, MD, Reid Wainess, BS, Gilbert R. Upchurch, Jr., MD,
Thomas W. Wakefield, MD, and Peter K. Henke, MD, Ann Arbor, Michigan
The aim of this study was to characterize patients requiring hospitalization for severe chronic
venous insufficiency (CVI) at the local and national levels and to analyze factors related to
primary amputation. An administrative database (Nationwide Inpatient Sample, 1988-2000) and
a single institution (1992-2000) were reviewed using the International Classification of Diseases,
9th ed., Clinical Modification, codes for CVI, excluding phlegmasia and concomitant peripheral
vascular occlusive disease codes. Demographics, clinical course, and outcomes were as-
sessed. Descriptive, univariate, and multivariate statistical analyses were used; p < 0.05 was
considered significant. Nationally, CVI occurred with a mean incidence of 92/100,000 admis-
sions, of which 55% were women, having a mean age of 65 years and a median length of stay of
7 days. Mean hospital charges were $13,900 and did not change significantly over time. Acute
deep vein thrombosis affected 1.3%, amputation was performed in 1.2%, and in-hospital mor-
tality was 1.6% The local cohort included 67 patients with a mean age of 51 years; a majority
were men (60%), and 85% were C6 (of Clinical-Etiologic-Anatomic-Pathophysiology [CEAP]).
Patients averaged 23 clinic visits and a median of one hospitalization for CVI care over a 44-
month follow-up. Twelve patients (18%) underwent a CVI-related amputation (one transmeta-
tarsal amputation, nine below-knee amputations, and two above-knee amputations). They had
fourfold more CVI-related hospitalizations, greater preoperative chronic narcotic use than non-
amputee patients (85% vs. 58%), but less ongoing wound care needs (25% vs. 89%) (all p
values < 0.05). However, no significant difference in long-term mortality, number of clinic visits,
duration of symptoms, antibiotic courses, or prior venous-related surgeries was found. In those
with amputation, ambulatory status was maintained in 75% at 15-month follow-up. The phy-
siological and economic costs of severe CVI are significant and have not decreased over more
than a decade. Amputation for CVI-related nonhealing wounds has a reasonable outcome.
Future therapy must focus on prevention of CVI sequelae.
INTRODUCTION
Venous thromboembolism (VTE) is a common and
devastating medical illness that affects hospitalized
medical and surgical patients alike. Two primary
sequelae result: pulmonary embolism and chronic
venous insufficiency (CVI). While good anticoag-
ulant prophylaxis and treatment exist for deep vein
thrombosis (DVT),1 a significant percentage of pa-
tients develop postphlebitis-related CVI. Less com-
mon causes of CVI are primary valvular
incompetence and congenital absence of venous
valves.2-4 Patients affected by this are generally
younger and often still working.5-7
Severe CVI manifestations of swelling, pain, and
ulceration are estimated to occur in 15-40% of
patients with DVT at 8 years.6 These manifestations
occur more often with postphlebitic syndrome than
primary valvular dysfunction. Healing time is var-
iable but often protracted.3 A prospective study of
250 patients with venous stasis ulceration (VSU)
who were treated with compression demonstrated
57% and 75% of ulcers healed at 10 weeks and 16
weeks, respectively.8 However, VSU recurrence is
common, particularly in patients not compliant
with compression therapy; and few series have
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follow-up greater than 24 months.8,9 In addition,
the socioeconomic impact of VSU is significant.9 In
the United States alone, direct medical costs for the
annual treatment of VSU have been estimated to be
between $150 million and $1 billion, with an
estimated 2 million lost workdays.3,10
The available therapies for CVI manifestations
are generally nonsurgical, with exercise, weight
loss, elastic compression stockings, and wound
care.4,8,11,12 While superficial venous ablation has
shown promise in a prospective, randomized
trial,13 deep system insufficiency reconstructions
have variable results outside of specialized centers
and few have been subjected to randomized pro-
spective evaluation.14,15 Although VSU rarely
necessitates amputation, patient debilitation and
discomfort can be significant. Patients with severe
CVI manifestations (C5-6 of the Clinical-Etiologic-
Anatomic-Pathophysiology [CEAP] classification16)
frequently report a reduction in quality of life: 81%
of patients experience decreased mobility and 57%
report severe limitation in mobility.7,12
Because many of these patients require numer-
ous clinical visits as well as occasional hospitaliza-
tions, the goal of this study was to evaluate the
current national epidemiology, incidence, and cost
of CVI and then to review a local series of patients
who were admitted with CVI-related wound
problems and characterize their clinical course
outcomes, including those who underwent primary
amputation.
METHODS
This study utilized two databases. The first is the
Nationwide Inpatient Sample (NIS), an adminis-
trative database that is a 20% stratified random
sample of all hospital discharges in the United
States and includes years 1988-2000. The data-
base is maintained by the Agency for Health Care
Research and Quality as part of the Health Care
Cost and Utilization Project.17 Patients were
identified by the International Classification of Dis-
eases, 9th ed., Clinical Modification18 (ICD-9CM),
hospital primary discharge codes for CVI-related
diagnoses: postthrombotic syndrome, 459.1; ve-
nous insufficiency, 459.81; VSU, 454.0; and deep
vein phlebitis, 451.11. Coexistence of acute DVT
was defined by ICD-9CM code 481.1. Patients in
this group who had concomitant codes for
peripheral vascular occlusive disease (PVOD;
440.21, 440.22, 440.23, 440.24, 440.29) and
phlegmasia (451.19) were excluded to increase
the specificity for venous-related disease out-
comes. Procedural codes for amputation below
the knee (BKA) or above the knee (AKA) (84.10,
84.15, 84.17) were denoted for the same hospi-
talization as the index CVI-coded patients. Out-
come measures evaluated were amputation rate,
length of stay (LOS), mortality, and inflation-ad-
justed cost of hospitalization.
The local series included consecutive patients
over a period of 8 years (1992-2000) using the same
diagnostic codes to isolate these hospitalized inpa-
tients. Only patients who were hospitalized at least
once for their CVI-related wound problems were
included. All patients had a VSU at some point as
the cause for index admission and were cared for by
the Vascular Surgery Service at the University of
Michigan. The size and locations of the various ul-
cers were not determined as they varied signifi-
cantly over time. A majority of the patients had CVI
diagnosis confirmed with either ascending/
descending venography or air plethysmography,
using standard positive criteria.19 During the time
frame analyzed, duplex diagnosis of venous insuf-
ficiency was not routinely used. Patients with a
history of phlegmasia were excluded, as were those
with interventions (e.g., surgical bypass or endo-
vascular) performed for PVOD. A detailed review of
the patients electronic medical charts identified
demographic data including age, gender, anticoag-
ulation status, CEAP classification (based on clinic
and discharge summary descriptors), and duration
of symptoms. Medical resource utilization data,
including clinic visits, number of courses of antibi-
otics, narcotic pain medication usage, duration of
outpatient follow-up for CVI care, number of clinic
visits and hospital admissions, and need for venous-
related surgery. CVI-related surgeries included
varicosity excision, split thickness skin grafting
(STSG) to the ulcer bed, subfascial endoscopic per-
forator surgery (SEPS), venous valve reconstruc-
tion, and venous bypass procedures. For those
patients who were lost to follow-up or deceased, the
ambulatory status was abstracted from the last clinic
documentation.
Statistical analysis utilized the Mann-Whitney U
or Student t-test for continuous variables and the
chi-squared or Fisher exact test for univariate
analysis. Logistical regression with dichotomous
variables was used to determine independence of
associated factors with specific outcomes of mor-
tality and amputation. Evaluation of the local data
with smaller patient numbers utilized univariate
analysis only. SPSS (Chicago, IL) statistical software
was used. p < 0.05 was deemed significant. The
study was approved by the University of Michigan
Institutional Review Board.
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RESULTS
Nationally, from 1988 to 2000, CVI-related diag-
noses accounted for a mean of 92 per 100,000 pa-
tient admissions without significant change over
time (Fig. 1). In this cohort, 55% were women,
with a mean age of 65 years and a median LOS of 7
days (range 1-143 days). Mean inflation-adjusted
hospital charges were $13,900, with little variation
over the time period studied (Fig. 2). Acute DVT
was a codiagnosis in 1.3%, and amputation was
performed in 1.1%. In-hospital mortality was 1.6%
(Table I). Logistical regression was done to deter-
mine independent factors associated with mortal-
ity, BKA, and AKA (Table II). While administrative
databases are limited in the specificity of patient
factors that can be analyzed, mortality was pri-
marily determined by age, emergent or urgent
admission, associated medical diseases, as well as
need for BKA and AKA. BKA (n = 889) was asso-
ciated with elective admission category (e.g., ur-
gent and emergent admission type was associated
with lower risk of amputation) as well as older age.
Female gender was protective, but no significant
association with diabetes, renal failure, coexistence
of an acute DVT, or race was found. A similar
predictive distribution of associated factors was
shown with AKA (data not shown), though the
number of patients having this procedure associ-
ated with CVI was very low (n = 80).
At the local level, 67 patients were included,
with a mean age of 51 years; 60% were men
(Table III). Most patients had active VSU, with 85%
having C6 classification, and averaged 23 clinic
visits for their CVI care. The median number of
hospitalizations was one over a 44-month mean
follow-up. Of this group, 12 patients underwent a
CVI-related amputation: one transmetatarsal
amputation (TMA), nine BKA, and two AKA. All in
the amputee group were C6 class and had fourfold
more hospitalizations, and a greater proportion
used narcotics chronically for pain than the no-
namputee group (all p < 0.05). Not surprisingly,
fewer patients required ongoing wound care after
Fig. 1. Hospital admissions (cases) for
primary diagnostic coded CVI-related
discharges per 100,000 patient discharges
1988-2000.
Fig. 2. Inflation-adjusted hospital care cost
(in dollars) for CVI-related discharge codes
1988-2000.
Table I. National cohort demographics
Number 80, 857
Age (years) 65 ± 18





LOS (days, median) 7
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amputation compared with nonamputees. Im-
portantly, those patients undergoing an amputa-
tion were unlikely to have significant PVOD as the
affected limb mean ankle brachial index was 0.93
(n = 5) or no pulse deficits were noted in the chart.
One patient had a perioperative flap infection that
required flap revision, but salvage of the BKA was
maintained.
No significant difference in long-term mortality,
number of clinic visits, antibiotic courses, duration
of symptoms, or prior venous-related surgeries was
found. Specifically, the types of venous-related
surgery in the amputee group included varicose
excision (n = 1, 7%), SEPS (n = 1, 7%), STSG
(n = 2, 14%), valve reconstruction (n = 4, 31%),
and veno-veno bypass (n = 1, 7%); while the
nonamputee group had a similar distribution: var-
icosity excision (n = 13, 23%), SEPS (n = 7, 13%),
STSG (n = 15, 27%), valve reconstruction (n = 8,
15%), and veno-veno bypass (n = 8, 15%). Long-
term mortality was 19% for the entire group at 44-
month follow-up and was not significantly differ-
ent between amputees and nonamputees
(p = 0.24).
DISCUSSION
The current report substantiates other reports in
that CVI with resultant limb swelling, pain, and
ulceration is a common disease that incurs signifi-
cant morbidity and cost.3,5,7,12,20,21 The epidemio-
logical data reinforce both the significant economic
Table II. Logistic regression
Factor Odds ratio 95% Confidence interval p
Mortality Age > 55 years 3.1 2.1-4.4 < 0.001
Admission type
Urgent 1.48 1.21-1.82 < 0.001
Emergent 2.1 1.7-2.5 < 0.001
BKA 3.8 2.5-5.9 < 0.001
AKA 5.1 3.4-7.4 < 0.001
Renal failure 4.5 2.7-7.6 < 0.001
BKA Age > 55 years 1.67 1.2-2.2 0.003
Female 0.50 0.41-0.62 < 0.001
Admission type
Urgent 0.55 0.42-0.72 < 0.001
Emergent 0.67 0.53-0.85 < 0.001
Nonsignificant associations for mortality included gender (p = 0.26), race, VTE, and diabetes. Nonsignificant associations for BKA
included presence of diabetes, renal failure, VTE, and race.
Table III. Local series
Patient characteristics (n = 67) Total Nonamputees Amputees p
Age (years) 51 ± 2 50 ± 4.4 57.3 ± 2.3 NS
Gender 41 men, 27 women 32 men, 23 women 9 men, 4 women NS
C6 class (%) 56 (85%) 45 (81%) 11 (100%) NS
Reflux + obstruction (%) 25 (37%) 20 (36%) 5 (42%) NS
Number of clinical visits 23 ± 3 21 ± 2.8 31.27 ± 10 NS
Duration of CVI symptoms (months) 45 ± 4 43.9 ± 29.8 51± 8 NS
Hospitalizations (median) 1.0 1.0 4.0 <0.001
Venous surgeries 59 (88%) 35 (63%) 8 (67%) NS
Mean number of antibiotic courses 2.7 ± 0.5 2.6 ± 0.8 3.3 ± 0.4 NS
Chronic patient narcotic use (%) 43 (64%) 32 (74%) 11 (85%) 0.04
Compression stockings (%) 48 (72%) 44 (75%) 4 (33%) NS
Ongoing wound care (%) 52 (78%) 49 (89%) 3 (25%) <0.001
Warfarin (Coumadin, %) 33 (49%) 28 (49%) 5 (38%) NS
Ambulatory 54 (90%) 55 (100%) 9 (75%) NS
Mortality 12 (19%) 8 (15%) 4 (33%) NS
Follow-up (months) 44 ± 4 45 ± 4 34 ± 8 NS
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impact and patient morbidity associated with se-
vere CVI (e.g., C6 classification). Discouragingly,
the current study showed that neither inflation-
adjusted mean hospital charge nor LOS decreased
over the last decade. This may reflect little
advancement in the basic therapy for severe CVI.
At this time, advanced VSU requires an intense
regimen of wound care, compression, chemical and
mechanical debridement, and antibiotics if neces-
sary. The national data do not include the costs
associated with outpatient CVI care, the setting in
which most patients receive care, and hence
underestimates the true overall costs. In one series,
the mean cost for outpatient wound care over a 90-
day period approached $6,000.22 Another study
reported outpatient treatment costs of VSU care
ranging $1,444-2,711 over a 10-week period.20
While a large number of clinic visits was docu-
mented, the burden for the patient and family in
travel time, loss of work hours, and ongoing home
care was not quantified. Similarly, the cost and
physiological impairment related to chronic use of
narcotics and antibiotics can also only be specu-
lated.
While the national amputation rate of 1.2% is
likely accurate, it may overestimate the true
number who had this for CVI-related problems due
to limited specificity in identifying patients by ICD-
9CM coding. Despite efforts to exclude patients
with coexistent arterial disease, this may not have
completely eliminated other disease processes, such
as severe infection, that may have resulted in an
amputation. However, urgent or emergent admis-
sion was actually associated with lower amputation
risk in this group, suggesting a planned admission
for these amputation procedures. That is, we
speculate that patients who underwent a CVI-re-
lated amputation were electively admitted for such
and that this was not done routinely in sicker pa-
tients. Similarly, the fact that diabetes mellitus and
renal failure were not associated with the evaluated
outcomes suggests that this patient population is
different from most arterial vascular disease pa-
tients who undergo amputation. While mortality
was increased in the national series among those
undergoing amputation, this was likely due to
underlying associated diseases or a generally
debilitated condition not able to be objectified by
the limitations of an administrative data set23 and
was quite low at  1%.
At the local level, our series was small and
lacked the power to discern differences in patient
disease parameters that would predispose toward
ultimately requiring an amputation. While the
overall amputation rate was 18%, significantly
higher than the national data, this represents a very
select series with all end-stage tertiary referral pa-
tients. Further, our group consisted of patients
admitted solely for CVI-related wound complica-
tions and/or operations related to this. The national
data set was broader in inclusivity. This tenet is
supported by the fact that all amputees were C6
class, most having nearly a decade of CVI-related
symptoms and ulceration, a significant number of
hospitalizations, and requiring chronic narcotics for
pain control as well as numerous prior venous
reconstructive surgeries. Unlike patients who have
amputations secondary to arterial disease, these
patients seem to have reasonable longevity, reha-
bilitation potential, and likely better use of a pros-
thesis than those who have arterial disease, where
death and disability rates are significant.24 For
example, no patient in this series required a higher-
level amputation, in contrast to many with
amputations for arterial disease. Approximately
three-quarters of amputated venous patients were
ambulatory, in contrast to an average rate of 30-
40% at our hospital (unpublished observations).
VSU often occurs as a sequela of previous DVT.
Numerous investigators have found higher rates of
ulcer recurrence in patients without compression
therapy, and better results are often obtained in
controlled, intensive trials. This study did not di-
rectly assess VSU healing, though the fact that most
had ongoing clinic visits and hospitalizations re-
flects the relapsing nature of VSU. While those with
significant PVOD requiring an intervention were
excluded from the local cohort, patients with mild
PVOD were not; and this may also have contrib-
uted to the need for amputation, though the mean
ankle brachial index was nearly normal. However,
not all patients in this series had this objectively
determined preoperatively. The presence of mild
arterial disease coexistent lymphedema and dia-
betic foot problems may contribute to poor wound
healing.10 Further investigations into the effect of
mild arterial insufficiency as well as diabetes,
coexistent VTE, and hemodialysis-dependent renal
failure on VSU healing may be warranted to better
prognosticate who might benefit from an amputa-
tion, though none of these was predictive from the
NIS data. Similarly, because of the recurring nat-
ure, severity, and location of the VSUs in this series,
size was not evaluated in the current study but is
known to correlate with healing.25
While DVT treatment with anticoagulation
effectively treats acute thrombus, a significant
percentage of patients go on to develop postph-
lebitic syndrome and CVI.4,6,11,26 More intensive
efforts should be made in the prevention of DVT by
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vascular surgeons, as well as early preventive
education of CVI by nonvascular surgeons in par-
ticular. Whether rapid and complete DVT throm-
bolysis via a catheter-directed approach compared
with standard anticoagulation is more efficacious
has yet to be determined.27 However, early expe-
rience with this technique suggests fewer long-
term CVI sequlae.28 Currently, early ambulation
and compression stocking therapy after acute DVT
and rapid achievement of therapeutic heparin
anticoagulation should decrease the incidence of
later severe CVI manifestations.29 For example,
institution of stocking compression (20-40 mm Hg
graded) started within 2-3 weeks after acute DVT
reduced subsequent severe CVI by 50%.11 This
measure has also been shown to be cost-saving but
has yet to be fully reimbursed.30
The limitations of this study are several. First, the
NIS database lacks a certain specificity with relation
to patient disease and outcome. While we used the
primary discharge diagnosis codes of venous insuf-
ficiency and limited this to patients who did not
have concurrent PVOD codes to remove patients
who might have had an amputation for another
reason, this is not totally specific. Furthermore,
whereas the data are quite accurate with regard to
certain demographics, mortality, and LOS, the pre-
dictors for patient-specific outcomes are more var-
iable as the compilation of these data depends on
trained coders rather than physicians or nurse
abstractors. Second, the local data and the operative
decision to amputate were surgeon-specific, and no
evidence-based protocols were used. Some amputee
patients had mild PVOD and diabetic wound prob-
lems that likely contributed to the decision, but
inclusion into this cohort was based firmly on re-
view of the primary amputation indication in the
medical record. There is a lack of literature sup-
porting or refuting amputation for CVI sequelae
with the exception of phlegmasia cerulea or
phlegmasia alba dolens when gangrene is present,
and these patients were specifically excluded in the
current series. Thus, the recommendations from
this series may not be applicable to all institutions.
In conclusion, severe CVI is a costly and mor-
bid disease that, because of its chronicity and
rarely life-threatening prognosis, receives little
national attention. In highly selected patients
who have failed venous reconstructive surgeries,
amputation may be reasonable therapy for
chronic VSU and/or intractable associated pain.
These sobering data with regard to cost, magni-
tude of clinical and hospitalization utilization, and
amputation rate lend further support to the rec-
ommendations that better prophylactic anticoag-
ulant protocols be instituted in hospitalized
patients to prevent DVT from occurring and that
rapid evidence-based therapy be applied for those
with established DVT.
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